Table 1.

Outline of the distinguishable nanotherapeutic tools designed for ovarian cancer treatment [19].

Nanosystems	Polymer–Drug Conjugates	Dendrimers	Polymer Micelles	Liposomes	Solid Lipid Nanoparticles
Size	≤10 nm	2–10 nm	10–100 nm	100–200 nm	50–1000 nm
Structural characteristics	Macromolecular structure	Macromolecular Tree-like structure	Spherical Supramolecular Core shell structure	Spherical bilayer vesicle structure	Spherical, bilayer-nanocapsular structure
Carrier composition	Water-soluble polymer	Hyperbranched polymer chains	Amphiphilic di and tri-block copolymers	Phospholipid, cholesterol membrane lipids	Solid lipid emulsifier water
Drug incorporation strategy	Covalent conjugation requiring functional groups on drug and polymer	Covalent conjugation requiring functional groups on drug and polymer	Noncovalent encapsulation/compatible with hydrophobic drugs	Noncovalent encapsulation/compatible with hydrophilic drugs	Noncovalent encapsulation/compatible with hydrophilic drugs
	PEG-paclitaxel & HPMA copolymer-doxorubicin—phase II trials SMANCS & CDP870 (Cimza)- Approved	Dendrimer- docetaxel & Viva gel- phase II & III trials PSMA-targeted dendrimers & Avidimer- dendrimers- Approved	CRLX- 101&NKTR-102- phase II/III clinical trials Genexol- PM- Approved	SGT53-01& MCC- 46 phase I clinical trials Doxil, Ambisome & DaunoXome- Approved	SLNs with [Gd-DTPA(H2O)]2− and [Gd-DOTA(H2O)]− compounds preclinical trials [31]. Diazemuls & Diprivan- Approved